Proteasomes are large, multicatalytic protein complexes that cleave cellular proteins into
peptides. There are many distinct forms of proteasomes that differ in catalytically active
subunits, regulatory subunits, and associated proteins. Proteasome inhibitors are an
important class of drugs for the treatment of multiple myeloma and mantle cell lymphoma,
and they are being investigated for other diseases. Bortezomib (Velcade) was the first
proteasome inhibitor to be approved by the US Food and Drug Administration. Carfilzomib …